INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Status:
Withdrawn
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability and to determine the
recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care
chemotherapy regimens in participants with advanced solid tumors.